Dandekar Atul 4

What Happened
Atul Dandekar, Chief Strategy & Business Officer (CSBO) of Maze Therapeutics (MAZE), exercised option-related shares and sold stock on June 29, 2026. The filing shows an exercise/acquisition of 7,500 shares at $10.42 per share (cost $78,150) and an open-market sale of 7,500 shares at $28.02 per share (proceeds $210,150). The filing also records a separate derivative disposition of 7,500 shares reported at $0.

Key Details

• Transaction date: 2026-06-29. Sale price: $28.02 x 7,500 = $210,150. Exercise price: $10.42 x 7,500 = $78,150.
• Net gross proceeds (sale minus exercise cost): $210,150 − $78,150 = $132,000 (before taxes/fees).
• Shares owned after the transaction: not specified in the provided filing details.
• Footnotes of note:
  • F1: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted Sept 29, 2025.
  • F2: The reported total includes 1,442 shares acquired under the company’s ESPP (exempt from Section 16 reporting rules).
  • F3: The option was fully vested (vested on March 17, 2025).
• Filing timeliness: Form 4 was filed 2026-07-01 for a 2026-06-29 transaction (within the standard reporting window); no late filing indicated.

Context

• This pattern — exercising options and selling an equal number of shares the same day — generally reflects a cashless exercise or sale to cover exercise costs/taxes; the filing’s separate $0 derivative disposition may represent net settlement or withholding, as reported.
• The sale was executed under a pre-established 10b5-1 plan, which is a prearranged trading plan that channels insider sales and reduces timing concerns.
• Facts only — this reports insider liquidity from exercised options and an open-market sale; it is not a direct signal of company outlook.